Platform
Built around our patented Proximity Extension Assay (PEA) technology, Olink’s flexible proteomics offering covers a broad a range of study sizes and multiplexing levels. Run projects yourself or send your samples for expert analysis.
Our PEA technology is a game-changer for proteomics.
Olink offers high-quality protein biomarker discovery based on a flexible and scalable technology platform. We have taken proteomics to the next level by enabling high-throughput, large scale analysis of thousands of proteins simultaneously, while using less than a drop of blood and maintaining exceptional levels of specificity, sensitivity and dynamic range.
Bring the power of Olink into your own lab
With the right instrument set-up and training, you can run Olink kits in-house and add our game-changing proteomics platform to your technology suite, or partner with us as a trained service provider to help make our technology available to researchers throughout the world.
Assay validation
Olink places quality and transparency at the heart of everything that we do. All assays are subject to rigorous validation and quality control and this data is freely shared with our customers. Make the right decisions in your research based on data you can trust.
Data normalization and standardization
White papers
This white paper describes how Olink data is processed and normalized to generate our Normalized Protein eXpression (NPX) values from an Olink study.
Pre-analytical variation in protein biomarker research
White papers
This white paper highlights some of the factors to consider when collecting, storing, and handling human blood samples for use in protein biomarker studies.
Development and validation of customized PEA panels
White papers
This white paper describes a proof-of-principle study where a customized 19-plex panel was developed and optimized for future clinical utility.
White papers
This white paper describes the Proximity Extension Assay (PEA) technology that underlies Olink’s panels for protein biomarker discovery, development, and implementation.
It’s all relative – 4 reasons why biomarker discovery commonly uses relative quantification
White papers
In this white paper, four reasons why relative quantification remains the prevalent method for biomarker discovery are provided.
Ensuring quality with flexibility- Olink® Flex validation & verification
White papers
This white paper transparently presents some of the results from our verification and validation tests carried out during the development of Olink Flex.
Measuring protein biomarkers with Olink
White papers
This white paper compares data from Olink studies with single- and multiplex technologies, with added tips on how to work with protein data from multiple platforms.
Strategies for design of protein biomarker studies
White papers
This white paper describes important aspects of study design to consider when planning your future research.
Olink innovation story
Olink Proteomics was forged from a history of proteomics innovation and development that took place here in Uppsala. Read on to find out how this innovation influenced the creation of PEA and how Olink continues to honor this spirit today.
The promise of proteomics
Together with our customers, Olink is accelerating proteomics to better understand human biology and develop future healthcare. We are on a journey to explore the low-abundance plasma proteome to uncover actionable insights that can drive the development of precision medicine.
Our community
Olink is much more than a provider of world-class products and services. The “Olink community” isn’t just a phrase, as witnessed by the important collaborative projects we have facilitated and a growing number of customer consortia, committed to the sharing of Olink data to accelerate progress in key disease areas.
2947
Biomarker assays
~881 million
Protein data points generated
1281
Publications listed on website